Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
OCULAR THERAPEUTIX, INC (OCUL)
|
Add to portfolio |
|
|
|
| Price: |
$15.89
| | Metrics |
| OS: |
79.4
|
M
| |
-2939
|
% ROE
|
| Market cap: |
$1.26
|
B
| |
-290
|
% ROIC
|
|
Net cash:
|
$11.2
|
M
| |
$0.14
|
per share
|
|
EV:
|
$1.25
|
B
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($81.9)
|
M
| |
|
|
|
EBIT
|
($84.0)
|
M
| |
|
|
| EPS |
($1.16)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| Revenues | 51.5 | 43.5 | 17.4 | 4.2 | 2.0 | 1.9 | 1.9 | 1.8 |
| Revenue growth | 18.3% | 150.1% | 311.7% | 112.4% | 3.5% | 1.9% | 7.8% | 126.7% |
| Cost of goods sold | 4.5 | 4.4 | 2.1 | 2.3 | 0.5 | 0.5 | 0.4 | 0.3 |
| Gross profit | 47.0 | 39.1 | 15.3 | 1.9 | 1.5 | 1.5 | 1.4 | 1.4 |
| Gross margin | 91.2% | 89.9% | 88.0% | 45.0% | 76.6% | 76.2% | 76.5% | 81.8% |
| Sales and marketing | 39.9 | 35.2 | 26.6 | 24.5 | 4.9 | 17.0 | 6.7 | 3.9 |
| Research and development | 53.5 | 50.1 | 28.7 | 41.1 | 36.9 | 30.9 | 27.1 | 26.6 |
| General and administrative | 32.2 | 31.9 | 22.9 | 22.1 | 18.8 | 15.5 | 11.0 | 9.2 |
| EBIT | -78.7 | -78.0 | -62.8 | -85.8 | -59.1 | -61.9 | -43.3 | -38.2 |
| EBIT margin | -152.7% | -179.3% | -361.1% | -2029.9% | -2970.8% | -3220.1% | -2296.0% | -2182.7% |
| Pre-tax income | -71.0 | -6.6 | -155.6 | -86.4 | -60.0 | -63.4 | -44.7 | -39.7 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -71.0 | -6.6 | -155.6 | -86.4 | -60.0 | -63.4 | -44.7 | -39.7 |
| Net margin | -138.0% | -15.1% | -894.3% | -2043.3% | -3014.0% | -3296.2% | -2369.0% | -2271.3% |
| |
| Diluted EPS | ($0.86) | ($0.08) | ($2.56) | ($1.91) | ($1.57) | ($2.20) | ($1.80) | ($1.71) |
| Shares outstanding (diluted) | 82.6 | 82.2 | 60.8 | 45.3 | 38.1 | 28.8 | 24.8 | 23.2 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|